Skip Navigation

Profile

Gregory L. Kucera, Ph.D.Wake Forest School of Medicine

Gregory L. Kucera, Ph.D.

Associate Core Director,
Professor,


Contact Information

Academic: 336-716-6348 | Department: 336-716-4464

Education & Training

  • B.S., Davidson College, 1982
  • Ph.D., Wake Forest University, 1987
  • Fellowship, University of Vermont, 1990
Gregory L. Kucera, Ph.D.

Gregory L. Kucera, Ph.D.

Associate Core Director, Comprehensive Cancer Center
Professor, Hematology & Oncology
Physiology & Pharmacology
Cancer Biology

Research Interests

Antineoplastic Agents; Acridines; Platinum; Deoxycytidine; Organoplatinum Compounds
More »

Contact Information

Academic: 336-716-6348 | Department: 336-716-4464

Recent Publications

The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS.. PLoS One. 2017;12(6):e0179798.

Improving nucleoside analogs via lipid conjugation: is fatter any better?. Alexander P, Kucera G, Pardee TS.. Crit Rev Oncol Hematol. 2016;100():46-56.

Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors. Yang M, Pickard AJ, Qiao X, Gueble MJ, Day CS, Kucera GL, Bierbach U.. Inorg Chem. 2015;54(7):3316-3324.

Investigating the cellular fate of a DNA-targeted platinum-based anticancer agent by orthogonal double-click chemistry. Qiao X, Ding S, Liu F, Kucera GL, Bierbach U.. J Biol Inorg Chem. 2014;19(3):415-426.

Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent. Ding S, Pickard AJ, Kucera GL, Bierbach U.. Chemistry. 2014;20(49):16164-73.

Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study. Pickard AJ, Liu F, Bartenstein TF, Haines LG, Levine KE, Kucera GL, Bierbach U.. Chemistry. 2014;20(49):16174-87.

Tuning the subcellular distribution and target selectivity of cytotoxic platinum-intercalator conjugates [abstract]. Pickard AJ, Liu F, Bartenstein TF, Haines LG, Levine KE, West TK, Kucera GL, Bierbach U.. Abstr Pap Am Chem Soc. 2014;247():295-MEDI.

Targeting cancer-related kinases with metal-functionalized inhibitors [abstract]. Yang M, Pickard AJ, Wright MV, Kucera GL, Bierbach U.. Abstr Pap Am Chem Soc. 2014;247():142-MEDI.

Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer. Ding S, Qiao X, Kucera GL, Bierbach U.. Chem Commun (Camb). 2013;49(24):2415-2417.

Using fluorescent post-labeling to probe the subcellular localization of DNA-targeted platinum anticancer agents. Ding S, Qiao X, Suryadi J, Marrs GS, Kucera GL, Bierbach U.. Angew Chem Int Ed Engl. 2013;52(12):3350-3354.

Compositions and methods for double-targeting virus infections and targeting cancer cells. Kucera L, Ishaq KS, Morris-Natschke SL, Fleming RA, Kucera GL, inventors; Wake Forest University Health Sciences, assignee.. Canada patent CA 2,445,565. 2013 July 9. 2013;():.

Novel phospholipid conjugates double-targeted HIV. Morris-Natschke SL, Fleming RA, Kucera GL, inventors; Wake Forest University Health Sciences, assignee.. United States Patent US 8,138,200. 2012 Mar 20. 2012;():.

Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells. Qiao X, Zeitany AE, Wright MW, Essader AS, Levine KE, Kucera GL, Bierbach U.. Metallomics. 2012;4(7):645-652.

Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. Ding S, Qiao X, Kucera GL, Bierbach U.. J Med Chem. 2012;55(22):10198-203.

Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. Graham LA, Suryadi J, West TK, Kucera GL, Bierbach U.. J Med Chem. 2012;55(17):7817-7827.

Compositions and methods for double-targeting virus infections and targeting cancer cells. Kucera L, Ishaq KS, Morris-Natschke SL, Fleming RA, Kucera GL, inventors; Wake Forest University Health Sciences, assignee.. Japan patent JP 5031162; 2012 July 6. 2012;():.

Biomedical applications of targeting platinum conjugates to DNA secondary structural motifs [abstract]. Pickard AJ, West TK, Kucera GL, Bierbach U.. Abstr Pap Am Chem Soc. 2011;241():161-INOR.

Inhibition of DNA synthesis by a platinum-acridine hybrid agent leads to potent cell kill in nonsmall cell lung cancer. Smyre CL, Saluta G, Kute TE, Kucera GL, Bierbach U.. ACS Med Chem Lett. 2011;2(11):870-874.

Unusual reactivity of a potent platinum-acridine hybrid antitumor agent. Graham LA, Wilson GM, West TK, Day CS, Kucera GL, Bierbach U.. ACS Med Chem Lett. 2011;2(9):687-691.

Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agents. Rao L, West TK, Saluta G, Kucera GL, Bierbach U.. Chem Res Toxicol. 2010;23(7):1148-1150.

Phospholipid/deoxycytidine analogue prodrugs for the treatment of cancer. Pickin KA, Alexander RL, Morrow CS, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL.. J Drug Del Sci Tech. 2009;19(1):31-36.

Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis. Eiter LC, Hall NW, Day CS, Saluta G, Kucera GL, Bierbach U.. J Med Chem. 2009;52(21):6519-6522.

Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. Kheradi AR, Saluta G, Kucera GL, Day CS, Bierbach U.. Bioorg Med Chem Lett. 2009;19(13):3423-3425.

Compositions and methods for targeting cancer cells. Kucera L, Fleming R, Ishaq K, Kucera G, Morris-Natschke S, inventors; Wake Forest University Health Sciences, assignee.. United States patent US 7,638,528. 2009 Dec 29. 2009;():.

Tuning the DNA conformational perturbations induced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups. Choudhury JR, Guddneppanavar R, Saluta G, Kucera GL, Bierbach U.. J Med Chem. 2008;51(11):3069-3072.

Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinum-acridines. Ma Z, Saluta G, Kucera GL, Bierbach U.. Bioorg Med Chem Lett. 2008;18(13):3799-3801.

A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. Ma Z, Choudhury JR, Wright MW, Day CS, Saluta G, Kucera GL, Bierbach U.. J Med Chem. 2008;51(23):7574-7580.

Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Barnes AP, Miller BE, Kucera GL.. Gynecol Oncol. 2007;104(2):443-450.

Photo-induced cytotoxicity of prodigiosin analogues. Park G, Tomlinson JT, Misenheimer JA, Kucera GL, Manderville RA.. Bull Korean Chem Soc. 2007;28(1):49-52.

Effect of the diamine nonleaving group in platinum--acridinylthiourea conjugates on DNA damage and cytotoxicity. Guddneppanavar R, Choudhury JR, Kheradi AR, Steen BD, Saluta G, Kucera GL, Day CS, Bierbach U.. J Med Chem. 2007;50(9):2259-2263.

Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Lentz SS, Miller BE, Kucera GL, Levine EA.. Gynecol Oncol. 2007;106(1):207-210.

Compositions and methods for targeting cancer cells. Kucera L, Ishaq K, Morris-Natsche S, Kucera G, Fleming R, inventors; Wake Forest University Health Sciences, assignee.. Unites States patent US 7,309,696. 2007 Dec 18. 2007;():.

Photoinduced cytotoxicity and thioadduct formation by a prodigiosin analogue. Tomlinson JT, Park G, Misenheimer JA, Kucera GL, Hesp K, Manderville RA.. Org Lett. 2006;8(21):4951-4954.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Gregory L. Kucera, Ph.D.

Gregory L. Kucera, Ph.D.

Associate Core Director, Comprehensive Cancer Center
Professor, Hematology & Oncology
Physiology & Pharmacology
Cancer Biology

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.